- Home
- SGMT vs OPP Comparison
SGMT vs OPP Comparison
Compare SGMT & OPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | SGMT | OPP |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Finance/Investors Services |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.6M | 198.2M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | SGMT | OPP |
|---|---|---|
| Price | $5.21 | $7.71 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $27.00 | N/A |
| AVG Volume (30 Days) | ★ 352.1K | 98.8K |
| Earning Date | 06-10-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 14.41% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4,523.58 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.73 | $7.69 |
| 52 Week High | $11.41 | $8.77 |
Technical Indicators
Market Signals| Indicator | SGMT | OPP |
|---|---|---|
| Relative Strength Index (RSI) | 41.75 | 33.64 |
| Support Level | $4.97 | N/A |
| Resistance Level | $6.49 | $8.01 |
| Average True Range (ATR) | 0.34 | 0.06 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 7.02 | 4.17 |
Price Performance
Historical ComparisonAbout SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
About OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.
RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.